Johnson & Johnson
Latest Johnson & Johnson News and Updates
Bristol-Myers Squibb Saw Improved Eliquis Sales in 3Q16
Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of key drug Eliquis. This segment contributed nearly 18% of total revenues for 3Q16.
Demographics Driving Conservative Investment? Bernstein Says No
After stating that the market isn’t in a low return environment, Richard Bernstein moved on to discuss the reasons cited by many for conservative asset allocation.
The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics
On September 16, 2016, Johnson & Johnson announced the acquisition of Abbott Medical Optics, a subsidiary of Abbott Laboratories, and its stock fell ~0.3%.
Pfizer’s Hospira Deal: Catching Up a Year Later
On September 13, 2015, Pfizer (PFE) completed its acquisition of Hospira for $17 billion.
Pfizer’s Essential Health Business: What You Need to Know
In this series, we’ll discuss in detail how Pfizer plans to revive growth for the falling Essential Health business.
Why Is Sanofi Expanding in the CHC Space?
Sanofi (SNY) plans to become a leading company in the CHC business. The asset swap will exclude Boehringer Ingelheim’s CHC business in China.
Understanding Sanofi’s Strategic Priority
As of June 30, 2016, the animal health business was Sanofi’s operating segment. It will remain an operating segment until the transaction closes.
A Look at Pfizer’s Innovative Health Business
In the second quarter of 2016, Pfizer (PFE) reorganized its Innovative Pharmaceutical and Consumer Healthcare operations as the Innovative Health business segment.
How AbbVie Expects Risankizumab to Be a Transformative Therapy
AbbVie (ABBV) expects its investigational drug Risankizumab to be a transformative therapy for psoriasis.
What Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16?
Sanofi’s Consumer Healthcare segment includes Allegra, Doliprane, Nasacort, and other products. It reported a 4.3% decline in revenues to 800 million euros.
How Is Varian Positioned in the Particle Therapy Business?
Varian Medical Systems (VAR) had gross orders value of $310 million in 2015.
Medtronic’s Minimally Invasive Therapies Group: Major Drivers
Medtronic plans to launch more than 80 products over the next three years.
A Look at Medtronic’s Geographic Strategy in 2016
Globalization is one of Medtronic’s (MDT) key growth strategies.
What Drives Medtronic’s Restorative Therapies Group’s Growth?
Medtronic’s (MDT) Restorative Therapies Group (or RTG) segment, formed around seven years ago, has a strong market position today.
What Drives Medtronic’s Cardiac Vascular Group’s Revenues?
Medtronic’s (MDT) Cardiac and Vascular Group (or CVG) is its largest segment.
What Risks Does Novartis Face?
Novartis is exposed to legal risks, including patent litigations, other product-related litigation, commercial litigation, government investigations, and prohibition rules.
What Are Novartis’s Key Business Segments?
Novartis’s new structure includes only three business segments: pharmaceuticals, Alcon, and Sandoz.
Company Overview: An Introduction to Intuitive Surgical
Intuitive Surgical is a pioneer of minimally invasive robotic surgery. It develops and manufactures da Vinci surgical systems and related instruments.
What Does Intuitive Surgical’s Business Model Look Like?
Intuitive Surgical (ISRG) defines its business model as a “razor/razor blade” model. What does this mean?
Inside Gilead Sciences’ Involvement in TAF Therapies
On March 01, 2016, the FDA approved Gilead Sciences’ TAF-based HIV drug, Odefsey, for the treatment of certain HIV-1 afflicted patients.
Understanding Boston Scientific’s MedSurg Segment
Boston Scientific’s (BSX) MedSurg segment contributes around 33% to the company’s total revenues and is the company’s second-largest segment.
Overview of Boston Scientific, a Leading Medical Device Company
Starting in 2011, Boston Scientific (BSX) has undertaken cost-cutting programs and reorganization efforts to turn the company’s battered financials around. In 2014, BSX started registering positive growth and profitability.
Why Abbott Laboratories Is a Leader in Nutritional Products
Abbott Laboratories’ Nutritional Products segment is the company’s leading segment, growing at a fast pace, with rapidly increasing margins and revenues.
What Is a Bridging Study?
A bridging study on a drug is an additional study performed in a new region to provide clinical data on safety, efficacy, dosage, and dose regimen.
What’s the Drug Approval Process in Japan?
The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.
Zimmer Biomet’s Competition in the Hip Implant Market
Zimmer Biomet (ZBH) is one of the leading hip implant providers in the United States, with approximately 31% market share.
Zimmer Biomet Faces Market Share Erosion in the Knee Implant Market
Zimmer Biomet (ZBH) is the leading provider of knee implants in the United States. It has approximately 40% market share, followed by Stryker, Johnson & Johnson, and Smith & Nephew.
How Is Medtronic’s Globalization Strategy Driving Its Growth?
Medtronic’s (MDT) growth is driven by three of the company’s core strategies—therapy innovation, globalization, and economic value.
Zimmer Biomet’s Capital Allocation Strategy and Shareholder Value
Zimmer Biomet has spent $125 million in share repurchases so far in 2016. In February, it authorized up to $1 billion of the company’s common stock for share repurchases.
What Could Drive Amgen’s Kyprolis Sales in 2016?
Amgen expects Kyprolis to continue capturing the global multiple myeloma (or MM) market in 2016. The drug has established itself as a backbone therapy for relapsed MM.
How Do Johnson & Johnson’s Valuations Compare to Peers?
On March 17, 2016, Johnson & Johnson (JNJ) was trading at a forward PE (price-to-earnings) multiple of ~16.5x compared to the industry average of ~19.6x.
How Johnson & Johnson Hopes to Boost Its Medical Device Segment
Johnson and Johnson’s (JNJ) medical device business segment comprises of cardiovascular, diabetes care, orthopedics, surgery, and vision care divisions.
Why Procter & Gamble Is Selling Some of Its Brands
Procter & Gamble is on a mission to trim brands that are holding back its overall financial performance.
Truven: IBM’s Latest Buy, Attempt to Push Watson
On February 18, 2016, IBM announced the acquisition of Truven Health Analytics for $2.6 billion. Truven provides cloud-based healthcare data and analytics.
Growth and Profitability: How Does Stryker Do It?
Between 2012 and 2014, Stryker (SYK) entered into a number of mergers and acquisition deals, investing ~$3.4 billion.
Can Consumer Healthcare Drive Sanofi’s Revenue?
The CHC (consumer healthcare) market forms a part of Sanofi’s (SNY) pharmaceutical segment.
Dissecting Abbott Laboratories: A Key Business Model Analysis
Since 2013, Abbott Laboratories has generated revenues from a diversified healthcare business spanning across geographies and four primary segments.
AbbVie’s Late-Stage Research Pipeline Could Boost Future Revenues
In partnership with Bristol-Myers Squibb, AbbVie is exploring elotuzumab to treat relapsed refractory multiple myeloma. The drug also received a breakthrough therapy designation from the FDA on May 19, 2014.
Understanding the Geographical Segmentation of Stryker
While Stryker is a global medical tech company focused on expanding its presence across international markets, the US makes up ~68% of its total revenues.
Understanding Stryker’s Neurotechnology and Spine Segment
Stryker’s Neurotechnology and Spine segment reported an increase of 5% in net sales in 2014, driven by increased demand for neurotechnology products.
Sizing up Stryker’s Business Model in 2015
Stryker offers a diversified portfolio of more than 60,000 products and services, with a focus on quality outcomes at lower costs through collaborations.
Established Pharmaceuticals Segment of Abbott Laboratories
Abbott’s Established Pharmaceuticals segment is a consumer-oriented segment with a consumer mix of around 75% self-pay consumers and 25% third-party payers.
Mapping Abbott Laboratories’ Geographic Strategy
Abbott Laboratories is a global healthcare company that sees 70% of its total revenues generated in markets outside the United States.
Risks Faced by Becton, Dickinson and Company
As it is susceptible to industry risks, Becton, Dickinson and Company (BDX), or BD, is transforming its business model.
An Overview of Becton, Dickinson and Company’s Business Model
On October 1, 2015, BD underwent organizational restructuring to better align its business model to the strategic vision and goals of the company.
Why Technology Is a Key Driver in the US Medical Device Industry
Traditionally, the United States has been home to the most advanced technological inventions in the medical device industry.
How Economic and Demographic Factors Affect Medical Device Industry
Though the medical device sector displays significant resilience towards changes in the economic environment, economic factors do impact short-term demand substantially.
What Are the Medical Device Approval Processes in Major Markets?
In most countries, the approval process varies across different categories of devices classified as per their risk profiles.
Why Are Patents Necessary for Medical Device Companies?
Medical device companies are driven by innovation and inventions that involve high research and development (or R&D) costs.
Gauging Medtronic’s Geographic Strategy in 2015
Medtronic’s US market YoY growth rate was 22% in 2015, compared to a 2% growth in 2014, whereas its emerging markets have grown by 23% in 2015.